Chest
Clinical InvestigationsCOPDMajor Components of the Direct Medical Costs of α1-Antitrypsin Deficiency
Section snippets
Materials and Methods
In the current study, a questionnaire (available from Dr. Mullins on request) addressing the previous 12-month period was sent to the 688 respondents to our earlier report.3 The questionnaire addressed the following areas: demographic characteristics; utilization of health services due to AAT deficiency and other health problems; and treatment costs for AAT deficiency. Specifically, information was sought regarding costs due to the following: α1-proteinase inhibitor; health insurance premiums;
Results
Responses were received from 292 of the 688 individuals to whom questionnaires had been sent (42.4%). The response rates for PI*ZZ individuals was 42.7% vs 41.8% for non-PI*ZZ subjects. Of the 292 respondents, 23 were excluded from analysis (20 because the questionnaires lacked cost information, and 3 because the total cost estimates were outliers, exceeding the group mean values by 10 times the SD). Thus, the results presented are based on 269 respondents (39.1% of those persons who had been
Discussion
The results of this survey of direct health-care costs associated with AAT deficiency show the following: (1) annual total health-care costs are high (mean range, $36,471 to $46,114; median range, $12,485 to $37,100), with estimates varying (by up to 20.9 to 66.3%) according to the method used for managing missing data; (2) total costs for PI*ZZ individuals showed a trend to exceed those for non-PI*ZZ individuals; (3) the use of IV augmentation therapy accounted for more than half of all
References (15)
- et al.
The direct medical costs of α1-antitrypsin deficiency
Chest
(2001) - et al.
Should health-care systems pay for replacement therapy in patients with α1-antitrypsin deficiency? A critical review and cost-effectiveness analysis
Chest
(2000) - et al.
The cost of treating COPD in the United States
Chest
(2001) - et al.
Pharmacoeconomic evaluation of COPD
Chest
(2000) World Health Organization's meeting on Alpha-1-Antitrypsin Deficiency
- et al.
Physical and social impact of α1-antitrypsin deficiency
Cleve Clin J Med
(1994) - et al.
Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease
Am J Public Health
(1991)
Cited by (19)
French clinical practice guidelines for the diagnosis and management of lung disease with alpha 1-antitrypsin deficiency
2022, Revue des Maladies RespiratoiresMeeting the challenge of COPD care delivery in the USA: A multiprovider perspective
2016, The Lancet Respiratory MedicineCitation Excerpt :More than two-thirds of both commercially insured and Medicare patients are routinely not prescribed any long-acting maintenance therapy.107 Additionally, access to and availability of augmentation therapy for some patients with α1 antitrypsin deficiency remain an issue.213 Patients with α1 antitrypsin deficiency incur approximately 6 times greater health-care costs than do COPD patients without such deficiency, with half of this cost being direct expenses associated with α1 antitrypsin augmentation.
Augmentation therapy of alpha-1 antitrypsin deficiency associated emphysema
2015, Revue des Maladies RespiratoiresCitation Excerpt :Randomised studies have demonstrated the efficacy of augmentation therapy on the decline in lung density. Augmentation therapy is a costly treatment (over 100 k€/year) and represents up to 60% of the medical costs for an emphysema patient in the United States [24]. The cost-effectiveness ratio is still debated.
Alpha-1 antitrypsin deficiency 50 years later
2014, Bulletin de l'Academie Nationale de MedecineAAT as a diagnostic tool
2005, Clinica Chimica Acta
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail:[email protected]).
This research was funded by the Alpha-1 Foundation.